HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pereira, A. Search for Related Content PubMed PubMed Citation Articles by Pereira, A.

Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection

From the Service of Hemotherapy and Hemostasis, Hospital Clínic, Barcelona, Spain

Correspondence: Arturo Pereira, Service of Hemotherapy and Hemostasis, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. E-mail: apereira{at}clinic.ub.es

A probabilistic model was used to compare cryoprecipitate to viral inactivated, commercial fibrinogen concentrate to evaluate with regard to the recipient’s risk of exposure to an emergent AIDS-like epidemic. In patients who occasionally need a therapeutic dose of fibrinogen, commercial fibrinogen would be marginally safer than cryoprecipitate if the new pathogen were sensitive to inactivation. But there is a potential high risk of exposure if the emerging agent withstands inactivation. In most of the analyzed scenarios, cryoprecipitate is safer than commercial fibrinogen as long as the odds that the new agent is sensitive to inactivation are lower than 1.000 to 1.

Key words: transfusion, cryoprecipitate, fibrinogen, infection, risk.

This article has been cited by other articles:

				A. Groner Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica, February 1, 2008; 93(2): e24 - e26. [Full Text] [PDF]

				A. Pereira Reply. Groner A. [Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007; 92:846-9]. Haematologica, February 1, 2008; 93(2): e27 - e27. [Full Text] [PDF]